Kekkan Biologics

Kekkan Biologics is a Paris-based, preclinical-stage biotech leveraging over 20 years of foundational research in tumor angiogenesis and lymphangiogenesis to build a pipeline of novel biologics. The company focuses on severe neovascular and fibrotic disorders, including metastatic cancers, by targeting key pathways in blood and lymphatic vessel formation. Founded by a complementary team of scientists and business professionals, it is incubated at SEMIA in Strasbourg and guided by a strong Translational Advisory Board of oncology experts. Kekkan operates as a platform company, aiming to generate multiple antibody candidates from its core research.

Platform for discovering and engineering therapeutic antibodies targeting validated receptors/factors in angiogenesis and lymphangiogenesis pathways.

Kekkan competes in the well-established anti-angiogenesis space (e.g., Roche/Genentech's Avastin) and the emerging lymphangiogenesis field. In fibrosis, it faces companies like Boehringer Ingelheim and Roche. Its differentiation hinges on novel target selection and potentially superior antibody engineering from its platform.